keyword
MENU ▼
Read by QxMD icon Read
search

PSMA-617

keyword
https://www.readbyqxmd.com/read/27922871/excellent-response-to-177lu-psma-617-radioligand-therapy-in-a-patient-with-advanced-metastatic-castration-resistant-prostate-cancer-evaluated-by-68ga-psma-pet-ct
#1
Wolfgang Roll, Axel Bode, Matthias Weckesser, Martin Bögemann, Kambiz Rahbar
Recently radiolabeled ligands targeting prostate specific membrane antigen (PSMA) have been introduced for diagnostics and treatment of prostate cancer. Labeled with Lutetium, PSMA radioligand therapy (RLT) is one of the most promising new treatments of metastatic castration refractory prostate cancer. We present images of Ga-PSMA PET/CT and parameters of response of a 75-year-old heavily pretreated metastatic castration refractory prostate cancer patient with extended bone metastases, showing an extraordinary biochemical response in PSA-levels concordant to SUV decline in bone metastases...
December 3, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27885457/-psma-targeted-radioligand-therapy-in-prostate-cancer
#2
M M Heck, M Retz, R Tauber, K Knorr, C Kratochwil, M Eiber
Radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) enables tumor-specific treatment directed against PSMA-overexpressing prostate cancer cells. Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with β‑radiating lutetium-177. These are currently applied in compassionate use programs to treat metastatic castration-resistant prostate cancer (mCRPC). PSMA-directed RLT is currently being offered in several nuclear medicine departments throughout Germany...
November 24, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27789722/preclinical-evaluation-of-18f-psma-1007-a-new-psma-ligand-for-prostate-cancer-imaging
#3
Jens Cardinale, Martin Schäfer, Martina Benešová, Ulrike Bauder-Wüst, Karin Leotta, Matthias Eder, Oliver C Neels, Uwe Haberkorn, Frederik L Giesel, Klaus Kopka
INTRODUCTION: In recent years several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Few of those had a high clinical impact for the treatment of patients suffering from prostate cancer. However, the number of fluorine-18 labeled tracers addressing PSMA is still limited. Therefore, we aimed at the development of a radiofluorinated molecule with emphasis on resembling the structure of the therapeutic PSMA-617. METHODS: The non-radioactive reference compound PSMA-1007 and the labeling precursor were built up by solid phase chemistry...
October 27, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27782913/post-therapeutic-dosimetry-of-177lu-dkfz-psma-617-in-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer
#4
Madhav P Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant A Damle, Ranjit K Sahoo, Amlesh Seth, Chandrasekhar Bal
OBJECTIVE: Lu-DKFZ-PSMA-617, a urea-based compound, binds to the extracellular domain of prostate-specific membrane antigen, thus providing an effective target for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Before its therapeutic use, it is necessary that the radiation dosimetry of this radiopharmaceutical be studied to determine the safe activity that can be administered in patients to prevent haematological, renal and liver toxicity. The present study thus aimed to assess the pharmacokinetics and dosimetry of Lu-DKFZ-PSMA-617 in CRPC patients...
January 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27765862/german-multicenter-study-investigating-177lu-psma-617-radioligand-therapy-in-advanced-prostate-cancer-patients
#5
Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, Uwe Haberkorn, Michael Schäfers, Markus Essler, Richard P Baum, Harshad R Kulkarani, Matthias Schmidt, Peter Bartenstein, Andreas Pfestroff, Ulf Lützen, Marlies Marx, Vikas Prasad, Winfried Brenner, Alexander Heinzel, Juri Ruf, Philipp Tobias Meyer, Martin Heuschkel, Maria Eveslage, Martin Bögemann, Wolfgang Peter Fendler, Bernd Joachim Krause
: (177)Lutetium labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration resistant prostate cancer (mCRPC). Initiated by the German Society of Nuclear Medicine a retrospective multicenter data analysis was started in 2015 to evaluate efficacy and safety of (177)Lu-PSMA-617 in a large cohort of patients. METHODS: 145 patients (median age 73 years, range 43-88) with mCRPC were treated with (177)Lu-PSMA-617 in 12 therapy centres between February 2014 and July 2015 with one to four therapy cycles and an activity range of 2 to 8 GBq per cycle...
October 20, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27715146/-64-cu-psma-617-pet-ct-imaging-of-prostate-adenocarcinoma-first-in-human-studies
#6
Bernhard Grubmüller, Richard P Baum, Enza Capasso, Aviral Singh, Yasaman Ahmadi, Peter Knoll, Andreas Floth, Sergio Righi, Shahin Zandieh, Carlo Meleddu, Shahrokh F Shariat, Hans Christoph Klingler, Siroos Mirzaei
AIM: The prostate-specific membrane antigen (PSMA) is a cell surface protein, which is overexpressed in nearly all cases of prostate cancer (PCa). PET imaging with (68)Ga-PSMA-HBED-CC has recently found widespread application in the diagnosis of recurrent PCa. In this study, the diagnostic potential of (64)Cu-labeled PSMA ligand (PSMA-617) PET in patients with PCa has been investigated. MATERIALS AND METHODS: The study was conducted simultaneously at two nuclear medicine centers, Austria (Vienna, Center 1) and Germany (Bad Berka, Center 2)...
October 7, 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27694178/the-rise-of-psma-ligands-for-diagnosis-and-therapy-of-prostate-cancer
#7
Ali Afshar-Oromieh, John W Babich, Clemens Kratochwil, Frederik L Giesel, Michael Eisenhut, Klaus Kopka, Uwe Haberkorn
The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors (123)I-MIP-1972 and (123)I-MIP-1095. A clinical breakthrough followed in 2011 with (68)Ga-PSMA-11 for PET imaging and (131)I-MIP-1095 for endoradiotherapy of metastatic prostate cancer...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27683041/preliminary-experience-with-dosimetry-response-and-patient-reported-outcome-after-177lu-psma-617-therapy-for-metastatic-castration-resistant-prostate-cancer
#8
Wolfgang P Fendler, Svenja Reinhardt, Harun Ilhan, Andreas Delker, Guido Böning, Franz J Gildehaus, Christian Stief, Peter Bartenstein, Christian Gratzke, Sebastian Lehner, Axel Rominger
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).Fifteen patients each received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n = 10) 177Lu-PSMA-617 at an eight to ten weeks interval. For safety monitoring, each treatment was followed by dosimetry with serial quantitative SPECT as well as inpatient and outpatient recording of adverse events...
September 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27616702/radioligand-therapy-with-177-lu-psma-617-of-metastatic-prostate-cancer-has-already-been-arrived-in-clinical-use
#9
LETTER
Hojjat Ahmadzadehfar, Markus Essler, Michael Schäfers, Kambiz Rahbar
No abstract text is available yet for this article.
December 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/27607162/successful-treatment-of-hepatic-metastases-of-hormone-refractory-prostate-cancer-using-radioligand-therapy-with-177lu-psma-617
#10
Xiao Wei, Carl Schlenkhoff, Claudia Sopora, Markus Essler, Hojjat Ahmadzadehfar
An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.
November 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27591896/formulation-of-clinical-scale-177-lu-psma-617-from-laboratory-to-clinics
#11
LETTER
Tapas Das, Mohini Guleria, Sharmila Banerjee
No abstract text is available yet for this article.
December 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/27587707/predictors-of-response-to-radioligand-therapy-of-metastatic-castrate-resistant-prostate-cancer-with-177lu-psma-617
#12
Justin Ferdinandus, Elisabeth Eppard, Florian Gärtner, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Stefan Hauser, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar
PURPOSE: Radioligand therapy (RLT) with (177)Lu-PSMA-617 (Lu-PSMA-617) (prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pre-therapeutic parameters on the therapeutic response measured by prostate-specific antigen(PSA) two months after RLT. METHODS: RLT was performed in 40 hormone and/or chemo refractory patients with distant metastases and progressive disease (mean age: 71...
September 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27554243/re-225-ac-psma-617-for-psma-targeting-alpha-radiation-therapy-of-patients-with-metastatic-castration-resistant-prostate-cancer
#13
Boris Hadaschik
No abstract text is available yet for this article.
August 20, 2016: European Urology
https://www.readbyqxmd.com/read/27506431/-177-lu-dkfz-psma-617-therapy-in-metastatic-castration-resistant-prostate-cancer-safety-efficacy-and-quality-of-life-assessment
#14
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). METHODS: Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic(68)Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Included patients then underwent quarterly (177)Lu-DKFZ-PSMA-617 therapy...
August 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27390158/225ac-psma-617-for-psma-targeted-%C3%AE-radiation-therapy-of-metastatic-castration-resistant-prostate-cancer
#15
Clemens Kratochwil, Frank Bruchertseifer, Frederik L Giesel, Mirjam Weis, Frederik A Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn, Alfred Morgenstern
: Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to (225)Ac-PSMA-617 therapy. METHODS: (68)Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of (225)Ac-PSMA-617 per kilogram of body weight was administered bimonthly...
December 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27350005/-177lu-psma-617-therapy-dosimetry-and-follow-up-in-patients-with-metastatic-castration-resistant-prostate-cancer
#16
Wolfgang P Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, Matthias Schmidt, Andreas Pfestroff, Ulf Lützen, Vikas Prasad, Alexander Heinzel, Martin Heuschkel, Juri Ruf, Peter Bartenstein, Bernd J Krause
Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015...
June 28, 2016: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/27342416/-18-f-labelled-psma-1007-shows-similarity-in-structure-biodistribution-and-tumour-uptake-to-the-theragnostic-compound-psma-617
#17
Frederik L Giesel, Jens Cardinale, Martin Schäfer, Oliver Neels, Martina Benešová, Walter Mier, Uwe Haberkorn, Klaus Kopka, Clemens Kratochwil
No abstract text is available yet for this article.
September 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27264278/prospects-of-medium-specific-activity-177-lu-in-targeted-therapy-of-prostate-cancer-using-177-lu-labeled-psma-inhibitor
#18
Sudipta Chakraborty, Rubel Chakravarty, Priyalata Shetty, K V Vimalnath, Ishita B Sen, Ashutosh Dash
Targeted radionuclide therapy using (177) Lu-labeled peptidomimetic inhibitor of prostate specific membrane antigen (PSMA) viz. PSMA-617 is emerging as one the most effective strategies for management of metastatic prostate cancer, which is one of the leading causes of cancer related death. The aim of the present study is to develop a robust and easily adaptable protocol for formulation of therapeutic dose of (177) Lu-PSMA-617 at hospital radiopharmacy using moderate specific activity (177) Lu available at an affordable cost...
July 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27187728/cocktail-therapy-of-177lu-psma-617-and-177lu-edtmp-in-patients-with-mcrpc-a-proof-of-principle-application
#19
Chandrasekhar Bal, Madhav Prasad Yadav, Sanjana Ballal
Prostate cancer is the second most common primary tumor affecting men worldwide. Among them, 10-20% develop castration resistant prostate cancer (CRPC). Ga-PSMA-PET/CT is an important theranostic agent for the evaluation of CRPC to assess the feasibility of treatment with Lu-PSMA-617 which is a novel therapeutic agent. Interestingly, in certain cases, we have observed non-PSMA-avid lesions despite raised sPSA levels. In this regard, we present a case of cocktail therapy applied using Lu-PSMA-617 and Lu-EDTMP therapy in a 38-year-old male CRPC patient with both soft tissue and extensive skeletal metastases...
August 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27150032/clinical-translation-of-177-lu-labeled-psma-617-initial-experience-in-prostate-cancer-patients
#20
Tapas Das, Mohini Guleria, Anil Parab, Chanchala Kale, Hina Shah, Haladhar D Sarma, Vikram R Lele, Sharmila Banerjee
OBJECTIVE: PSMA-617 is reported to exhibit very high binding affinity towards PSMA receptors, over-expressed on prostate cancer cells and therefore, (177)Lu-labeled PSMA-617 is expected to play a pivotal role in the clinical management of patients suffering from ca prostate. The objective of the present study is to formulate the patient dose of (177)Lu-labeled PSMA-617, pre-clinical studies in animal model and clinical investigation in limited number of prostate cancer patients as well evaluating its potential for theranostic application...
May 2016: Nuclear Medicine and Biology
keyword
keyword
119470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"